Dublin, April 17, 2026 (GLOBE NEWSWIRE) — The “Middle East and Africa Biosimilars Market: Industry Trends and Global Forecasts – Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players” report has been added to ResearchAndMarkets.com’s offering.
The Middle East and Africa biosimilars market is estimated to grow from USD 1.15 billion in the current year to USD 5.73 billion by 2035 at a CAGR of 19% during the forecast period, till 2035.
The biosimilars market in the Middle East and Africa is currently experiencing rapid growth, fueled by increased healthcare investments, a rising prevalence of chronic diseases such as diabetes and cancer, and favorable regulatory environments in prominent countries like Saudi Arabia, the UAE, and South Africa. Particularly in areas with limited resources, the pressing demands created by chronic illnesses like diabetes and cancer necessitate the use of biologics, yet their high costs often leave many patients unable to access them.
The biosimilars market is expected to grow significantly in the upcoming years as patents of biologics expire, paving the way for the introduction of biosimilars that closely mimic their original counterparts. Lately, the biologics sector has experienced considerable expansion, largely due to its increased effectiveness in managing chronic diseases.
Nonetheless, the high costs associated with biologics create major financial and healthcare obstacles. As the demand for biologics continues to increase, developers are exploring innovative approaches to create more affordable biologic products that maintain comparable safety and efficacy standards to optimize their investment returns.
Growth Drivers: Strategic Enablers of Market Expansion
The Middle East and Africa Biosimilars Market experiences robust growth driven by several key factors, including rising prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders and increased demand for affordable biologic alternatives. In addition, government initiatives such as streamlined regulatory pathways for biologics also propel market growth. Further, patent expiries of major drugs like Herceptin and Rituxan, enable local manufacturers to expand portfolios rapidly. Strategic partnerships with global firms, low-cost manufacturing capabilities, and a skilled workforce further position Middle East as one of the leading exporters.
Market Challenges: Critical Barriers Impeding Progress
Challenges persist in the Middle East and Africa Biosimilars Market despite the ongoing market growth, hindering faster adoption. High development costs, complex manufacturing processes requiring stringent quality controls, and risks of immunogenicity or structural variability raise entry barriers for smaller players in this market space. Further, regulatory hurdles, including evolving guidelines and the need for comparative clinical trials, result in delayed approvals. In addition, poor domestic production and R&D infrastructure the region lead to import dependency and supply disruptions. Market access issues, such as competition from branded generics, pricing pressures, and patent litigations from originator companies, also constrain growth.
Monoclonal Antibodies: Leading Market Segment
At present, the monoclonal antibodies segment holds almost 55% of the total market share in Middle East and Africa. This leading position is mainly due to their widespread application in the treatment of chronic illnesses such as cancer, rheumatoid arthritis, and various autoimmune disorders. However, the peptide segment is expected to expand at a faster CAGR throughout the forecast period.
Oncological Disorders: Dominating Market Segment
Currently, oncological disorders dominate the Middle East and Africa Biosimilars Market, capturing most the market share. This trend is further supported by an aging population, changes in lifestyle, and improved diagnostic techniques, necessitating affordable treatments, particularly for costly monoclonal antibody therapies. As a result, this presents attractive growth opportunities for biosimilar developers. Additionally, the hematological disorders segment is expected to experience a higher compound annual growth rate (CAGR) during the forecast period.
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
- The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
- The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
- The report allows for more effective communication with the audience and in building strong business relations.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 100 |
| Forecast Period | 2026 – 2035 |
| Estimated Market Value (USD) in 2026 | $1.15 Billion |
| Forecasted Market Value (USD) by 2035 | $5.73 Billion |
| Compound Annual Growth Rate | 19.0% |
| Regions Covered | Africa, Global, Middle East |
Key Players in Middle East and Africa Biosimilars Market
- AbbVie
- Amgen
- Biocon
- Celltrion Healthcare
- Dr. Reddy’s Laboratories
- Pfizer
- Roche
- Samsung Biceps
- Sandoz
- Teva Pharmaceutical Industries
- Viatris
Key Segments
By Drug Class
- Monoclonal Antibodies
- Proteins
- Peptides
- Others
By Therapeutic Area
- Oncological Disorders
- Autoimmune and Inflammatory Disorders
- Hematological Disorders
- Metabolic Disorders
- Other Disorders
By Type of Manufacturer
- Contract Manufacturers
- In-house Developers
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Complementary Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs Covering All Analytical Modules
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
For more information about this report visit https://www.researchandmarkets.com/r/f8skpe
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Middle Eastern and African Biosimilars Market
